Published on 18/12/2025
Summary of Safety and Clinical Performance (SSCP) Requirements under EU MDR
The Summary of Safety and Clinical Performance (SSCP) is a critical element of the European Union Medical Device Regulation (EU MDR) and serves to enhance transparency concerning the clinical performance of medical devices and combination products. This article serves as a comprehensive step-by-step guide outlining the SSCP requirements, aimed at regulatory affairs, quality assurance, and market access teams engaged in pharma regulatory consulting efforts within the EU, as well as global contexts.
1. Understanding the Framework of SSCP Requirements
The need for the SSCP stems from the EU MDR’s objective to ensure that the safety and performance of medical devices and combination products are adequately documented and communicated to healthcare professionals and patients. It emphasizes ongoing clinical evaluation and vigilance, aligning with the post-market surveillance (PMS) obligations stipulated under Article 83 of the regulation.
The SSCP has several aims:
- To provide clear and accessible information on the clinical performance and safety of devices.
- To serve as an aid in informed
1.1 Key Legislation and Guidelines
The SSCP requirements are defined in the EU MDR (Regulation (EU) 2017/745), particularly in Annex XIV, which details its specific components. Additionally, it is essential to consult the guidelines provided by the European Medicines Agency (EMA) and relevant clinical evaluation guidance documents. These resources help inform companies about the best practices for drafting and maintaining SSCP documents.
2. SSCP Documentation Requirements
Creating a robust SSCP involves understanding its mandatory content requirements as stipulated in the EU MDR. The following sections outline the necessary components of a compliant SSCP:
2.1 Device Identification and Description
The SSCP should begin with a clear identification of the medical device, including its name, classification, and intended use. In this section, manufacturers should also outline any relevant product codes and regulatory identifiers, including the Unique Device Identifier (UDI) if applicable.
2.2 Clinical Performance Data
A pivotal section of the SSCP involves the presentation of clinical performance data that supports the safety and effectiveness of the device. This should include:
- Clinical investigations conducted, including their protocols.
- Summaries of clinical data derived from investigations, literature, and PMS activities.
- A clear analysis of benefits versus risks associated with the device, including common adverse events.
2.3 Post-Market Surveillance (PMS) and Vigilance Plan
The SSCP must include a summary of the PMS plan, detailing how ongoing clinical performance will be monitored. Manufacturers should refer to EU Guidelines on PMS, which address various aspects of data collection, evaluation, and notification responsibilities, especially in the context of the pharmaceutical compliance consulting role.
2.4 Intended Users and Patient Population
This section must describe the intended users of the device, clarifying whether it is for use by healthcare professionals, the general public, or both. Providing demographic information about the patient population can help contextualize the clinical performance data and ease interpretation among users.
2.5 Summary of Risks and Benefits
This crucial section requires manufacturers to summarize the risks associated with the device vis-a-vis the intended benefits. It is vital to reference credible data sources and a comprehensive risk assessment strategy that adheres to ISO 14971, the international standard for risk management in medical devices. Highlighting this in the SSCP not only aligns with veeva pharmacovigilance practices but promotes a culture of proactive safety management and compliance.
2.6 References and Supporting Information
Last but not least, manufacturers should provide a comprehensive list of literature, studies, and guidelines referenced throughout the SSCP. This enhances the credibility of the document and supports its conclusions. Abiding by guidelines from international organizations such as the World Health Organization (WHO) can further enhance the reliability of the sources cited.
3. Preparing the SSCP for Regulatory Submission
Once the SSCP has been drafted, the regulatory submission process begins. In this section, we will outline the steps for ensuring successful submission under the EU MDR framework:
3.1 Internal Review and Approval
Before submission, the SSCP must undergo a rigorous internal review process. This includes cross-functional teams comprising regulatory affairs, quality assurance, and clinical affairs professionals. The objective of this review is to confirm that all relevant information has been accurately captured and presented according to regulatory requirements. Typically, it is advisable to follow a defined document control procedure to document approvals systematically.
3.2 Engagement with Notified Bodies
If the device is categorized under higher-risk classes (Class IIa, IIb, or III), submission must be made to a Notified Body. The SSCP will be an integral component of the technical file provided for evaluation. Engaging with the Notified Body early in the process can facilitate feedback on the SSCP content before formal submission.
3.3 Addressing Feedback and Revisions
The Notified Body may provide feedback or request revisions to the SSCP, which must be addressed promptly. It is critical to establish an efficient communication channel with the Notified Body for clarifications and to demonstrate a cooperative approach towards compliance. Responding to feedback effectively can help to expedite the approval process and enhance the overall quality of the clinical evaluation.
3.4 Finalizing and Distributing the SSCP
Once all relevant approvals have been secured, manufacturers should prepare the final document for distribution. The SSCP must be readily accessible to relevant stakeholders, including healthcare professionals and patients. Manufacturers should ensure that the SSCP is published in a manner that aligns with the Medical Device Coordination Group (MDCG) recommendations.
4. Maintaining Compliance After Submission
Post-submission compliance is paramount to ensure that the SSCP remains relevant throughout the lifecycle of the device. The following list highlights key considerations for maintaining compliance:
4.1 Ongoing Post-Market Surveillance Activities
Continuous monitoring of the device’s performance is essential to uphold the clinical claims made in the SSCP. Manufacturers should implement a robust PMS system aligned with ISO 13485 standards, leveraging real-world data to inform product updates and safety strategies.
4.2 Updating the SSCP
Regulatory requirements change frequently, and technology evolves rapidly. As new clinical data emerges, it may be necessary to revise the SSCP to reflect current safety and performance information accurately. An updated SSCP should be re-submitted if it significantly alters the clinical claims established earlier.
4.3 Training and Awareness
Training related to the SSCP should be conducted regularly for regulatory, quality assurance, and market access teams. This ensures that all stakeholders are aware of the clinical performance claims as well as the responsibilities concerning safety monitoring.
4.4 Document Control
Implementing a comprehensive document control system is critical to managing the various versions and updates of the SSCP. The system should accurately reflect the change history and allow for quick reference by internal stakeholders and compliance auditors.
Conclusion
The Summary of Safety and Clinical Performance (SSCP) is vital to ensuring that medical devices and combination products fulfill stringent safety and performance criteria under the EU MDR framework. By understanding the intricacies of preparing, submitting, and maintaining compliance pertaining to the SSCP, professionals in pharma regulatory consulting can significantly enhance their product’s posture within the regulatory landscape. A proactive approach to PMV (Post-Market Vigilance), continuous updating of the SSCP, and maintaining dialogue with regulatory bodies will foster a favorable regulatory environment and safeguard public health.